Evidence map›Paper›PMID 35452812›Full record

ArticleMicrobes and infection2022

Time dependent decline of neutralizing antibody titers in COVID-19 patients from Pune, India and evidence of reinfection.

Purwa Doke, Jayshree Sachin Gothankar, Prakash Prabhakarrao Doke, Milind Madhukar Kulkarni, Kiran Kishanrao Khalate, Shubham Shrivastava, Jayesh Rangrao Patil, Vidya Avinash Arankalle

Open access · greenAbstract read
In one paragraph

Article in Microbes and infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Purwa DokeDepartment of Medicine, Bharati Vidyapeeth Deemed University Medical College, Pune-Satara Road, Katraj, Pune 411043, Maharashtra, India.
Jayshree Sachin GothankarDepartment of Community Medicine, Bharati Vidyapeeth Deemed University Medical College, Pune-Satara Road, Katraj, Pune 411043, Maharashtra, India.
Prakash Prabhakarrao DokeDepartment of Community Medicine, Bharati Vidyapeeth Deemed University Medical College, Pune-Satara Road, Katraj, Pune 411043, Maharashtra, India.
Milind Madhukar KulkarniCivil Hospital, Aundh, Pune 411027, Maharashtra, India.
Kiran Kishanrao KhalateCivil Hospital, Aundh, Pune 411027, Maharashtra, India.
Shubham ShrivastavaDepartment of Communicable Diseases, Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth (Deemed to be University), Pune-Satara Road, Katraj, Pune, Maharashtra, India.
Jayesh Rangrao PatilDepartment of Community Medicine, Bharati Vidyapeeth Deemed University Medical College, Pune-Satara Road, Katraj, Pune 411043, Maharashtra, India.
Vidya Avinash ArankalleDepartment of Communicable Diseases, Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth (Deemed to be University), Pune-Satara Road, Katraj, Pune, Maharashtra, India. Electronic address: vidya.arankalle@bharatividyapeeth.edu.
Bharati Vidyapeeth Deemed University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo assess modulation of neutralizing antibody titers in COVID-19 patients and understand association of variables such as age, presence of comorbidity, BMI and gender with antibody titers.

methodsPatients (n = 100) diagnosed from 20th March 2020 to 17th August 2020 and treated at two large hospitals from Pune, India were included and followed up (clinical and serologic) for varied periods. IgG-anti-SARS-CoV-2 (Spike protein-based ELISA) and neutralizing antibody titers (NAb, PRNT) were determined in all the samples.

resultsOf the 100 patients enrolled initially (median 60 days of diagnosis), follow up samples were collected from 70 patients (median 106 days of diagnosis). Overall, NAb titers reduced significantly (p < 0.001) and as early as 3-4 months. During two visits, 20% and 7.1% patients reported some symptoms. At the first visit, NAb titers were higher in patients with severe disease (p < 0.001), comorbidities (p < 0.005), age <50 years (p < 0.05) and male gender (p < 0.05). Multivariate analysis identified older age (p < 0.001), duration post-diagnosis and female gender as independent variables influencing NAb titers (negative correlation, p < 0.05). During the follow-up, reduction in NAb titers was recorded in patients with comorbidity (p < 0.05), mild disease (p < 0.05), age <50 years (p < 0.05), higher BMI (p < 0.05) and male gender (p < 0.001). Serology identified six cases of asymptomatic reinfections.

conclusionsDecline of NAb titers was associated with age <50 years, mild disease, comorbidities, higher BMI and male gender. At the time of follow up, 8/70 (11.4%) patients lacked neutralizing antibodies. Evidence of 6 probable asymptomatic reinfections suggests waning of immunity, but, probable protection from clinical disease needing hospitalization.

Indexed as

COVID-19Antibodies, NeutralizingAntibodies, ViralFemaleHumansIndiaMaleMiddle AgedReinfectionAntibodies, NeutralizingAntibodies, ViralBMIComorbiditiesCOVID-19Neutralizing antibodiesReinfectionSeverity

Identifiers

PMID35452812
PMCPMC9020493
OpenAlexW4224238351

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.